Reasons for Discontinuation of Implanon among Users in Buffalo City Metropolitan Municipality, South Africa: A Cross-Sectional Study

Khungelwa Patricia Mrwebi, Daniel Ter Goon, Eyitayo Omolara Owolabi, Oladele Vincent Adeniyi, Eunice Seekoe, Anthony Idowu Ajayi


Early discontinuation of implanon, a long-acting, reversible contraceptive among reproductive age women in South Africa is a serious public health concern. The aim of this study was to examine the reasons for discontinuation of implanon among its previous users. This descriptive cross-sectional study involved 188 consecutively selected participants in two large family planning clinics in Buffalo Metropolitan Municipality, East London, South Africa. Descriptive statistics was conducted using SPSS version 22.0. The mean duration of use was 11.2±7.1 months. Side effects such as heavy bleeding, severe headache and painful arm were the main reasons for discontinuation of implanon (71.3%). Some participants discontinued implanon because they were receiving other medical treatments: 24 participants on the anti-retroviral drugs, one on antipsychotic and anti-tuberculosis drugs, respectively, necessitating removal. Few participants reported wrong positioning (3.2%) and desire for more pregnancies (4.3%) as reasons for discontinuation. The side effects of implanon were the reason for early discontinuation of implanon among women who still needed contraception. Pre-insertion counselling should empower women towards making informed decision on discontinuation and transition to other options. (Afr J Reprod Health 2018; 22[1]: 113-119).


South African Department of Health. National

Contraception and Fertility Planning Policy and Service Delivery Guides. Pretoria. 2012.

Tsui AO, Mcdonald-Mosley R and Burke AE. Family

planning and the burden of unintended pregnancies. Epidemiol Rev. 2010; 32:152–174.

Liu L, Becker S, Tsui A and Ahmed S. Three methods

of estimating births averted nationally by contraception. Popul Stud (Camb). 2008; 62(2):191–210.

Miller G. Contraception as development? New evidence

from family planning in Colombia. Econ J. 2009; 120(545):709-736.

Weldegerima B and Denekew A. Women's knowledge,

preferences, and practices of modern contraceptive methods in Woreta, Ethiopia. Res Social Adm Pharm. 2008; 4(3):302-307.

Blumenthal PD, Voedisch A and Gemzell-Danielsson

K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Human Repro Update. 2011; 17(1): 121-137.

Lince-deroche N, Harries J and Mullick S. Achieving

universal access to sexual and reproductive health services: the potential and pitfalls for contraceptive services in South Africa. South African Health Review. 2016; 9:208.

UNFPA. South Africa‘s family planning is above

average. 2012. Available from: [Accessed on 7th March, 2017]

Health 24. Woman goes through hell with Implanon

birth control implant. 2016. Available from: birth-control-implant-20160422. [Accessed on 7th March, 2017]

Adams B. Subdermal implants : a recent addition to the

choice of South African contraceptives. Professional Nurses Today. 2015; 19(2):32–34.

Patel M. Contraception: everyone‘s responsibility. S Afr

Med J. 2014; 104(9):644.

Goldstuck ND. Family planning in South Africa:

Missing essentials and desirables. South African Medical Journal, 105(11):904-905.

Croxato BB and Makarainene L. The

pharmacodynamics amd efficacy of implanon. An overview of the data. Contraception. 1998; 58(6 Suppl):91S-97S.

Ojule JD, Oranu EO and Enyindah CE. Experience with

Implanon in Southern Nigeria. Journal of Medicine and Medical Sciences, 2012; 3(11):710-714.

Winner B, Jeffery F, Peipert JF, Zhao Q, Buckel C,

Madden T, Allsworth JE and Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med. 366(21): 1998-2007.

World Health Organization (WHO). Medical eligibility

criteria for contraceptive use. A WHO family planning cornerstone. 4th edition. Geneva: WHO. 2010.

The National Institute for Health and Care Excellence.

Long-acting reversible contraception: the effective and appropriate use of long acting reversible contraception. London. RCOG Press, 2005.

Kluge J and Steyn P. Contraceptives: A guide to

product selection. S AfrFamPract. 2010; 52(6): 499-504.

Pushpa B, Sangita N, Shiyani A and Chitra T.

Implanon: Subdermal Single Rod Contraceptive Implant. J Obstet and Gynaecol India. 2011; 61(4): 422-425.

Burusie A. Reasons for Premature Removal of

Implanon among Users in Arsi Zone, Ohamia Region, Ethiopia. ReprodSyst Sex Disord. 2015: 4(1):1–6.

Ezegwui HU, Ikeako LC, Ishiekwene CI and Oguanua

TC. The discontinuation rate and reasons for discontinuation of implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Niger J Med. 2011; 20(4):448-450.

Mastor A, Si LK and Siti OZ. Users‘ perspectives on

implanon in Malaysia, a multicultural Asian country. Open Access Journal of Contraception. 2011; 2:79-84.

Green A. The five best contraceptives backed by

science. Evidence for Contraceptive option and HIV outcomes. 2017. Available from: [Accessed on 11th March, 2017]

Harvey C, Seib C and Lucke J. Continuation rates and

reasons for removal among Implanon users accessing family planning clinics in Queensland Australia. Contraception. 2009; 34(8), 39-56.

Komane. Review of breakthrough contraceptive,

implanon. SABC. 2015:1. Available from:

Birhane K, Hagos S and Fantahun M. Early

discontinuation of implanon and its associated factors among women who ever used implanon in Ofla District, Tigray, Nothernethiopia. International Journal of Pharma Sciences and Research. 2015; 6(3): 544–551.

Zerihun H, Biru A and Worku A. Implanon removal

experiences of women in Butajira. Ethiopian Journal of Health Development, 2015; 29(3):176–182.

Harper CC, Blum M, De Bocanegra HT, Darney PD,

Speidel JJ, Policar M and Drey EA. Challenges in translating evidence to practice: the provision of intrauterine contraception. Obstet Gynecol. 2008; 111(6):1359-1369.

Rocca CH and Harper CC. Do racial and ethnic

differences in contraceptive attitudes and knowledge explain disparities in method use? Perspect Sex Reprod Health. 2012; 44(3):150-158.

Chersich MF, Wabiri N, Risher K, Shisana O,

Celentano D, Rehle T and Rees H. Contraception coverage and methods used among women in South Africa: A national household survey. SAMJ 2017; 107(4), 307- 314.

Lakha F and Glasier AF. Continuation rates of implanon

in the UK: Data from an observational study in Clinical settings. Contraception. 2006; 74:287-289.

Shelton JD. Reduced Effectiveness of Contraceptive

Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good enough and for how long? Global Health: Science and Practice. 2015; 3(4): 528– 531.

Olivier Graesslin&TjeerdKorver (2008) The

contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience, The European Journal of Contraception &Reproductive Health Care, 13:sup1, 4-12, DOI: 10.1080/13625180801942754.


  • There are currently no refbacks.